Movement Disorders

Compared with healthy controls, those with isolated RBD performed significantly worse on all cognitive assessments except in tasks of executive function.

The senior vice president and chief scientific officer of the Parkinson’s Foundation detailed some of the potential reasons for the nearly 50% increase from the previously estimated rate. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 3, 2023.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 24, 2023.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

Researchers designed a new screening tool to assist nonmovement disorders specialists with identifying involuntary movements in patients aged at least 4 years of age with an inborn error of metabolism.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on recently published findings showing a nearly doubling of Parkinson disease incidence that previously reported. [WATCH TIME: 4 minutes]

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

Here's some of what is coming soon to NeurologyLive® this week.

Analysis on the EARLYSTIM trial assessing deep brain stimulation of the subthalamic nucleus in early Parkinson disease showed maintained speech intelligibility and nonspeech oral movements.

Neurology News Network for the week ending February 18, 2023. [WATCH TIME: 4 minutes]

Teva’s VMAT2 inhibitor was previously approved in a twice-daily formulation. The once-daily extended-release treatment, marketed as Austedo XR, is expected to be available later in 2023 in doses of 6 mg, 12 mg, and 24 mg.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 17, 2023.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

Investigators concluded that the therapeutic effectiveness of antiparkinsonian medications is short and limited for intolerable abdominal pain.

For controlling symptoms of Parkinson disease psychosis, pimavanserin had the most favorable effect size based on 2 major efficacy outcomes.

Dual-task effects were greater for patients with functional gait disorders than controls in gait speed and stride length, but not in stride time variability.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

Here's some of what is coming soon to NeurologyLive® this week.

Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.